Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1041 results about "Dermatologic disorders" patented technology

Virus-attenuated bovine nodular skin disease virus LSDV-75 and application thereof

The invention discloses a virulence-attenuated bovine nodular skin disease virus LSDV-75 and application thereof, and belongs to the technical field of attenuated strains. The invention aims to provide a bovine nodular skin disease virus vaccine strain which is sufficient in attenuation and good in immune effect. The invention provides a virulence-attenuated bovine nodular skin disease virus strain, which is named as sheep pox virus LSDV-75, has the preservation number of CCTCC NO: V2024114, and is preserved in the China Center for Type Culture Collection on December 2, 2024. The vaccine strain provided by the invention can be used as a vaccine candidate strain for safely and effectively preventing and controlling bovine nodular dermatosis.
Owner:HARBIN VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES (CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER HARBIN BRANCH CENTER)

Compositions and Methods for Preventing or Improving Premature Skin Aging

The invention provides a topical composition for preventing or treating skin aging, comprising at least one compound selected from the group consisting of ergothioneine, an analog or derivative thereof, or a dermatologically acceptable salt thereof. This topical composition improves skin's radiance, luminosity or texture, and rarely produces skin irritation. In another aspect, this invention provides a method for preventing or treating photoaging in a subject, comprising topical application of the composition of the invention.
Owner:NANJING NUTRABUILDING BIO TECH CO LTD

Isoxazoline parasiticide formulations

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
Owner:TARSUS PHARMACEUTICALS INC

Monoclonal antibody aiming at bovine nodular skin disease virus L1R protein

The invention belongs to the technical field of immunology and in vitro diagnosis, and relates to a monoclonal antibody aiming at bovine nodular skin disease virus (LSDV) L1R protein. According to the invention, the LSDV recombinant L1R protein with deletion of a transmembrane region (182-204aa) is obtained through expression; after a mouse is immunized by the protein, a monoclonal antibody 8D5 which is good in reactivity and specificity and aims at the LSDV L1R protein is screened out; heavy chain and light chain variable region sequences for coding the monoclonal antibody 8D5 are obtained; the monoclonal antibody 8D5 can be subjected to specific reaction with LSDV L1R protein, the recombinant protein L1R can be specifically recognized by bovine LSDV positive serum, meanwhile, the monoclonal antibody 8D5 can be used for establishing an LSDV ELISA antibody detection method, and a foundation is laid for LSDV diagnostic technology and vaccine research and development.
Owner:LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)

Isoxazoline parasiticide formulations and methods for treating blepharitis

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
Owner:TARSUS PHARMACEUTICALS INC

Skin cleansing formulation

A skin cleansing formulation is provided, comprising: a dermatologically acceptable vehicle; a dermatologically acceptable oil; and a deposition aid polymer, wherein the deposition aid polymer is a cationic dextran polymer, comprising a dextran polymer functionalized with quaternary ammonium groups; wherein the deposition aid polymer enhances the deposition of the dermatologically acceptable oil from the skin cleansing formulation onto mammalian skin.
Owner:DOW GLOBAL TECHNOLOGIES LLC +1

Therapeutic nucleic acids and methods of use thereof

An isolated nucleic acid that includes the nucleotide sequence: CGUCCGAUGGUAGUGGGUUAUCAG (SEQ ID NO: 12) is provided. In some embodiment, the nucleic acid includes at least one chemically-modified nucleotide. The nucleic acid and composition containing same find use in treating conditions associated with inflammation and / or fibrosis, for example, without limitation, heart conditions, such as hypertrophic myocardiopathy, myocardial infarction, and heart failure with preserved ejection fraction; muscle disorders, such as muscular dystrophy; skin disorders, such as scleroderma; and inflammatory conditions, such as autoimmune conditions or inflammatory conditions associated with a viral infection.
Owner:CEDARS SINAI MEDICAL CENT

Skin focus segmentation method and device based on ETMA-Net

PendingCN119067934AGood cross-domain generalization performanceSegmentation results are smoothImage enhancementImage analysisPattern recognitionImaging processing
The invention provides a skin focus segmentation method and device based on ETMA-Net, and relates to the technical field of medical image processing. The method comprises the following steps: acquiring a dermatoscope image to be segmented; the method comprises the following steps: constructing an ETMA-Net model, wherein the ETMA-Net model comprises an edge threshold guided parallel encoder, a grouped multi-scale Hadamard attention module, a multi-level feature aggregated jump connection module and a deep supervision decoder; carrying out training on the ETMA-Net model; and inputting the dermatoscope image into a trained ETMA-Net model to obtain a skin focus segmentation result. According to the method, feature information is fully utilized, the segmentation performance of the model can be improved while low parameter quantity and low calculation quantity are kept, and the method has excellent migration performance.
Owner:LIAONING TECHNICAL UNIVERSITY

Solid Personal Care Product and Method to Obtain Such Product

It is provided a personal care product comprising two subproducts: a first subproduct which is a freeze-dried solid composition comprising a thickening agent and an humectant; and a second subproduct which is a dried solid film comprising a thickening agent and an humectant; wherein the second subproduct is adapted to contain the first product, thereby acting as a first enveloping element covering the first product, wherein the first product and the second product are adapted to be separately manipulated as two independent products, and each provide a different or equal personal care function by being water-soluble. The personal care product is suitable for cosmetic, oral care, dermatological and pharmaceutical use. Said product can further comprise a second enveloping element comprising a synthetic polymeric film and on the inner part a thickening agent. Furthermore, the present invention is directed to a method to prepare said product.
Owner:UNIV INT DE CATALUNYA FUNDACIO PRIVADA

Canine atopic dermatitis animal model of and use thereof

PCT designated stage expiredWO2025116616A1Peptide/protein ingredientsPharmaceutical delivery mechanismEpicutaneous sensitizationClinical research
The present invention relates to a method for producing a canine atopic dermatitis animal model, a canine atopic dermatitis animal model produced thereby, and a use thereof. According to the present invention, a canine atopic dermatitis animal model is produced by skin stimulation on a dog through epicutaneous sensitization with ovalbumin at a concentration of 1 to 5 mg / ml once daily for 1 to 2 weeks and then with ovalbumin at a concentration of 1 to 5 mg / ml once daily for 2 to 8 weeks. The resulting animal model exhibits clinical symptoms of atopic dermatitis, changes in relevant factors such as increased expression levels of IgE and CCL17, and elevated expression levels of Th2-related cytokines IL-4, IL-31, and IL-13. Therefore, this invention enables the establishment of a standardized animal model for symptoms and Th2 immune responses appearing upon the onset of atopic dermatitis, and the model can be used in clinical studies for screening candidate agents for the prevention, alleviation, or treatment of atopic dermatitis.
Owner:KOREA RES INST OF CHEM TECH

Methods, systems, and / or devices for thermal treatments

ActiveUS12496253B2Bathing devicesTrigeminal nerve stimulationNose
A soaking device and methods of using are used to cool and / or to heat a face of a person for a purpose of inducing a desired and / or intended outcome in that person. The cooling and / or the heating of the face may be sufficient to induce the desired and / or the intended outcome in that person. The desired and / or intended outcome may relate to: release of at least one type of neurotransmitter; trigeminal nerve stimulation; (indirect) vagus nerve stimulation; transdermal drug delivery; bypass of the blood-brain-barrier (BBB); aesthetic medicine; cardiovascular; dermatological; ears, nose, and throat (otolaryngological); ophthalmological; neurological; psychological; endocrinological; and / or rheumatological benefits to that person. At least one step of the method may include receiving at least some of the face within an immersion-liquid for at least a minimum amount of time while the immersion-liquid is within a temperature-range and while the immersion-liquid is within the soaking device.
Owner:HYDROEFFACER CORP

Healthy Selfie (TM) -- Methods and Systems for Improving the Accuracy of Phone Images of a Pathology or Injury on a Body

This invention is a method, device, or system to guide a person concerning how to operate a conventional phone to record more-accurate images of a pathology or injury (e.g. such as a wound or skin lesion) on a body for remote medical evaluation purposes. In an example, machine learning and / or artificial intelligence can be used to guide the person concerning how to move a phone along a virtual arcuate path or shape in space over, across, or around the pathology or injury. In an example, this guidance can be auditory, visual, and / or tactile.
Owner:HOLOVISIONS

Composite polypeptide composition as well as preparation method and application thereof

The invention belongs to the technical field of biological medicine, and relates to a composite polypeptide composition as well as a preparation method and application thereof. According to the technical scheme, pH responsive polymer loaded oligopeptide-1, acetyl heptapeptide-4 and palmitoyl tripeptide-1 are adopted as a core, hyaluronic acid is adopted for wrapping, a hyaluronic acid layer adsorbs palmitoyl tripeptide-8, heptapeptide-6 and decapeptide-4, and the composite polypeptide with a core-shell structure is prepared and used for treating inflammatory skin diseases. In the acute stage of inflammation, the active ingredients on the outer layer quickly inhibit the activation of proinflammatory factors and immune cells and relieve red, swollen and heat pain, and the gel outer layer formed by hyaluronic acid realizes continuous release, prolongs the action time and supplements moisture to the skin; the pH-responsive polymer of the inner layer releases active ingredients at the inflammation part, so that relapse is prevented, and the skin barrier function is repaired. The composition plays a role from multiple dimensions of inflammation regulation, barrier repair, oxidation resistance and the like through a multi-layer structure design and a multi-component synergistic effect.
Owner:SHANDONG JITAI BIOTECH CO LTD

Traditional Chinese medicine composition for treating skin diseases and preparation method thereof

The invention discloses a traditional Chinese medicine composition for treating skin diseases and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 6-12 parts of radix notoginseng, 8-15 parts of radix salviae miltiorrhizae, 10-20 parts of rhizoma chuanxiong, 8-15 parts of rhizoma curcumae longae, 15-35 parts of radix angelicae sinensis, 3-8 parts of sandalwood, 3-8 parts of fructus aurantii immaturus, 40-60 parts of ramulus cinnamomi, 8-15 parts of rhizoma corydalis, 8-15 parts of rhizoma curcumae, 2-5 parts of flos carthami, 5-12 parts of radix puerariae, 8-15 parts of radix rehmanniae, 3-8 parts of pericarpium citri reticulatae and 8-15 parts of spica prunellae. The traditional Chinese medicine composition is prepared from 3-8 parts of radix trichosanthis, 15-35 parts of tribulus terrestris, 15-35 parts of cicada slough, 5-12 parts of stiff silkworm and 8-15 parts of rhizoma drynariae. According to a multi-target collaborative mechanism, network pharmacology proves that 12 pathological pathways such as IL-17A and the like can be regulated and controlled, and the TNF-alpha inhibition rate is 89% and the barrier repair speed is increased by 2.3 times through key component combination. According to a transdermal synergistic technology, the specific surface area of the medicine reaches 8.5 m < 2 > / g through superfine grinding, a Franz test shows that the penetration amount of tanshinone is increased by 3.7 times, and the onset time is shortened to 8.3 minutes. Dual scar regulation and control: the thickness of scars in 12 weeks is reduced by half through TGF-beta3 up-regulation and alpha-SMA inhibition, and the collagen order degree is improved by 3.2 times.
Owner:张机

Aloe extract-probiotic composite hydrogel for skin diseases of pets

The invention belongs to the technical field of medical preparations for pets, and particularly relates to an aloe extract-probiotic composite hydrogel for pet dermatosis, a preparation method comprises the following steps: under an aseptic condition, animal combined lactobacillus ZYpet-012 with the preservation number of CGMCC No.32008 is subjected to solid slant culture medium recovery and liquid culture, and then the animal combined lactobacillus ZYpet-012 with the preservation number of CGMCC No.32008 is subjected to freeze-drying to obtain the aloe extract-probiotic composite hydrogel for pet dermatosis. Centrifugally washing to obtain a probiotic suspension; the preparation method comprises the following steps: preparing blank hydrogel from carbomer 940, triethanolamine, zinc hyaluronate and the like; and mixing the aloe extract solution with the blank hydrogel, and then adding the probiotic suspension to prepare the composite hydrogel. According to the present invention, by using the anti-inflammatory, antibacterial and prebiotic characteristics of the aloe extract and combining the skin micro-ecology adjusting effect of the animal and the lactobacillus ZYpet-012, the prepared composite hydrogel can effectively treat the skin diseases of pets, and has advantages of nature, safety, accurate targeting and the like.
Owner:北京和益源生物技术有限公司

Wearable phototherapy device

Embodiments of the present invention provide a wearable phototherapy device, comprising a flexible substrate supporting a plurality of light-emitting elements configured to emit therapeutic light of one or more wavelengths. The substrate conforms to a treatment surface and may be integrated into a mask, wrap, patch, or garment insert. A conductive thin-film layer with an integrated metal-grid structure limits current to the light-emitting elements. The elements are arranged in one or more treatment zones, each independently addressable to provide wavelength and intensity control. A connector assembly enables selective attachment and detachment of the substrate to a power and control module. The device provides uniform, targeted illumination for dermatological, cosmetic, or therapeutic applications while maintaining ergonomic comfort.
Owner:SHENZHEN KAIYAN MEDICAL EQUIP CO LTD +1

Material for treating inflammatory skin diseases, preparation method and application

The invention discloses a material for treating inflammatory skin diseases, a preparation method and application, the inflammatory skin diseases comprise psoriasis and atopic dermatitis, and the material comprises cerium substituted molybdenum-based polyoxometallate. The application has the advantages that the CMB has reliable biological safety and excellent active oxygen scavenging capacity, and can effectively inhibit the level of ROS (reactive oxygen species) in cells at lower concentration, so that the inflammation activation of psoriasis or atopic dermatitis is inhibited, and the effect of treating psoriasis or atopic dermatitis is achieved; compared with a water-insoluble inorganic nano material, the CMB material can be dissolved in water, is not easy to retain in local tissues, is more easily metabolized by an organism, and is better in safety.
Owner:SHANGHAI DERMATOLOGY HOSPITAL

Application of polypeptide in preparation of medicine, food or health care product for treating obesity and complications thereof

The invention discloses application of a polypeptide in preparation of medicines, foods or health-care products for treating obesity and complications thereof, and belongs to the technical field of biological medicines. The polypeptides are human GPR15L polypeptides or mouse GPR15L polypeptides and polypeptide conjugates of the human GPR15L polypeptides or the mouse GPR15L polypeptides. The obesity treatment comprises the steps of reducing fat accumulation, promoting fat heat production and decomposition, increasing energy consumption and reducing body weight. Obesity complications include chronic inflammation, fatty liver, steatohepatitis, metabolic diseases, cardiovascular and cerebrovascular diseases, osteoarticular diseases, Alzheimer's disease, depression, tumors and skin diseases. The blood sugar and the body weight are reduced through a brand new action mechanism, so that the obesity and complications thereof are effectively treated.
Owner:THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV

Pyridone endoperoxide with antibacterial and antiviral activity and application thereof

The invention discloses pyridone endoperoxide with antibacterial and antiviral activity and application thereof, and belongs to the fields of organic compound synthesis and medical technology, food engineering and the like. The invention proves that the series of endoperoxides can effectively kill pathogenic bacteria, fungi and viruses, including propionibacterium acnes, escherichia coli, staphylococcus aureus, candida albicans, human papilloma viruses, herpes simplex viruses and the like. The internal peroxide designed by the invention has the capability of treating skin diseases, is expected to be developed into a first-line medicine for treating skin diseases caused by pathogen invasion, and mainly relates to bacterial skin diseases, fungal skin diseases and viral skin diseases caused by pathogen infection. Meanwhile, the series of endoperoxides can be used for treating oral infection, periodontitis, infection of shoulder and other joint operations, and bacterial infection such as pressure sores. In addition, the peroxides in the series can also be used in the fields of food preservation, disinfectant preparation and the like.
Owner:DALIAN UNIV OF TECH

(R)-3-(3-chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)morpholine derivatives and related compounds as bradykinin (BK) B2 receptor antagonist for treating skin diseases

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.
Owner:PHARVARIS GMBH

Roflumilast formulations with an improved pharmacokinetic profile

An improved method is provided for treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast. The improvement involves administering the roflumilast topically in a composition having a roflumilast release profile that produces in the patient a flattened plasma concentration time curve and a reduced Cmax relative to oral administration of a PDE4-inhibiting amount of roflumilast. Such disorders include inflammatory disorders such as inflammatory dermatoses, including psoriasis, atopic dermatitis and seborrheic dermatitis. Such disorders also include inflammatory diseases in a variety of organs, especially the lungs (asthma, COPD). Because of reduced side effects with topical administration due to the improved pharmacokinetics (PK) characteristics, it may be possible to provide higher systemic exposures (AUCs) with topical administration, resulting in greater therapeutic efficacy than with the oral route of administration.
Owner:ARCUTIS BIOTHERAPEUTICS INC

Isoxazoline parasiticide formulations and methods for treating blepharitis

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
Owner:TARSUS PHARMACEUTICALS INC

Traditional Chinese medicine formula for promoting blood circulation and removing toxicity and preparation method of nanogel of traditional Chinese medicine formula

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a blood-activating and detoxifying traditional Chinese medicine formula and a nanogel preparation method thereof. The invention provides a traditional Chinese medicine formula for promoting blood circulation and removing toxicity and a nanogel preparation method of the traditional Chinese medicine formula for promoting blood circulation and removing toxicity to solve the problem that in the prior art, a good external application traditional Chinese medicine formula capable of being used for skin with damp-heat toxin accumulation does not exist, and the traditional Chinese medicine formula for promoting blood circulation and removing toxicity and the nanogel preparation method of the traditional Chinese medicine formula for promoting blood circulation and removing toxicity comprise monarch drugs, ministerial drugs, adjuvant drugs and conductant drugs, the ministerial drugs comprise honeysuckle flowers, fructus forsythiae, paris polyphylla, cortex dictamni and fructus kochiae, the adjuvant drugs comprise radix salviae miltiorrhizae, flos carthami, garden balsam stems and centella asiatica, and the conductant drug comprises bletilla striata. The traditional Chinese medicine composition provided by the invention is precise and appropriate in compatibility and distinct in gradation, and can form a synergistic treatment chain of clearing heat, detoxifying, activating blood and promoting tissue regeneration, so that the wound healing speed of the skin surface is accelerated, and the traditional Chinese medicine composition has a relatively good curative effect on damp-heat and toxic stasis type skin diseases.
Owner:嘉兴市中医医院 +1

Extended skin color modulation compositions and methods

PCT designated stage expiredWO2024263606A1Cosmetic preparationsMake-upDERMATOLOGY/SKINDermatomal
The invention described here provides methods comprising administering a dermatologically suitable chromophoric composition comprising a chromophoric comprising dermal / subdermal chromophoric agent(s) (e.g., chromophoric vitamin(s) or minerals), and a chromophoric extension component to provide a coloration effect to the skin for an extended and sustained period (e.g., at least 3, 6, 9, 12, 15, or 18 months). In aspects, the coloration effect comprises a detectable or significant increase in reddening of at least part of the skin of a treated person. The chromophoric component and chromophoric extension component are typically are present in stable association, e.g., by comprising agent(s) that are covalently conjugated. The invention also provides compositions used in such methods and method of making such compositions.
Owner:TALEI BENJAMIN

Application of LCE5A as a target in the preparation of drugs for the treatment of inflammatory skin diseases including psoriasis

The present invention discloses an application of LCE5A as a target in the preparation of a drug for treating inflammatory skin diseases including psoriasis, wherein the LCE5A is mainly expressed on the epidermis; the present invention confirms through a series of experiments that LCE5A can effectively alleviate imiquimod-induced psoriasis-like skin inflammation in mice. The protein can significantly improve the barrier function of mouse skin, inhibit the release of proinflammatory factors and reduce the infiltration of inflammatory cells by regulating the proliferation and differentiation of keratinocytes. This provides important experimental support for the use of LCE5A in the preparation of drugs for skin diseases caused by skin barrier damage, as well as the development of functional skin care products. The experimental results clearly show that LCE5A exhibits significant therapeutic effects in a mouse psoriasis-like inflammation model, and its effect is safe and stable. The protein has a simple extraction and purification process, has good industrial production potential, and lays a solid foundation for clinical application.
Owner:覃莉

Systems and methods for skin color classification

Systems and methods for classification and / or analysis of skin color(s) are provided. The technology integrates artificial intelligence (AI) with dermatology to enhance skin color classification. The unique matching technique aligns skin images with the Fitzpatrick skin type palette through Euclidean distance matching, achieving higher precision in skin color classification compared to conventional methods.
Owner:FLORIDA INTERNATIONAL UNIVERSITY

Metal complex compounds as photosensitizers for photodynamic therapy

Electrically neutral complex compounds of formula I including any stereoisomer or E / Z isomer thereof wherein: M is Fe < 2 + >, Ru < 2 + >, Os < 2 + >, Co < 3 + >, Rh < 2 + >, Rh < 3 + >, Ir < 3 + >, Ni < 2 + >, Pd < 2 + >, Pt < 2 + > or Pt < 4 + >, in particular Ru < 2 + >; t and T'are H or (C1-C3)-alkyl; lig is a bidentate ligand, in particular 2, 2 '-dipyridyl (bpy) or 4, 7-diphenyl-1, 10-phenanthroline (BPhen); and A is an anion from a pharmaceutically acceptable acid, the electrically neutral complex compounds of formula I are useful in human therapy, in particular as photosensitizers (PS) in photodynamic therapy (PDT) of cancer, skin diseases, fungal infections or microbial infections. They are almost non-toxic under dark conditions at therapeutic doses and exhibit good to excellent photoactivity under hypoxic conditions. They can be used for PDT treatment of deep hypoxia tumors by using light within a far-infrared to near-infrared light treatment window.
Owner:UNIV DE BARCELONA +3